India’s Glenmark to study potential COVID-19 drug combination

0
72


BENGALURU: Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs – favipiravir and umifenovir – as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.



Follow The Himalayan Times on
Twitter
and
Facebook





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here